Global Atlas of ALLERGY

Total Page:16

File Type:pdf, Size:1020Kb

Global Atlas of ALLERGY GLOBAL ATLAS OF ALLERGY Published by the European Academy of Allergy and Clinical Immunology www.eaaci.org Allergy - Mechanisms Epidemiology and risk factors Allergy diagnosis TLAS Major Allergic Diseases A ERGY Other hypersensitivity diseases ALL Special considerations Management of allergic OF diseases GLOBAL Towards a comprehensive global strategy for the management of allergic diseases GLOBAL ATLAS OF ALLERGY Editors Cezmi A. Akdis Ioana Agache Editorial Board Pascal Demoly Peter Hellings Antonella Muraro Nikolaos G.Papadopoulos Ronald van Ree Published by the European Academy of Allergy and Clinical Immunology 2014 GLOBAL ATLAS OF ALLERGY EAACI EXECUTIVE COMMITTEE BOARD OF OFFICERS Nikos Papadopoulos, President Antonella Muraro, Secretary General Peter Hellings, Treasurer Ioana Agache, Vice-President Communication and Membership Pascal Demoly, Vice-President Education and Specialty Ronald Van Ree, Vice-President Congresses Cezmi A. Akdis, Past President SECTION CHAIRPERSONS Leif Bjermer, Asthma Carsten Bindslev-Jensen, Dermatology Cemal Cingi, ENT Carsten Schmidt-Weber, Immunology Susanne Lau, Pediatrics Alexandra Santos, Junior Members and Affiliates INTEREST GROUP REPRESENTATIVES Moises Calderon Karin Hoffmann-Sommergruber MEMBERS AT LARGE Lars K. Poulsen Tomas Chivato Thomas Werfel Beatrice M. Bilo Graham Roberts Musa Khaitov CHAIR EAACI PATIENT ORGANIZATION COMMITTEE Frans Timmermans ADJUNCT MEMBERS Fulvio Braido, CME Committee Chairperson Jan de Monchy, Specialty Committee Chairperson Jacques Gayraud, Ethics Committee Secretary Peter Schmid-Grendelmeier, Exam Committee Chairperson Marek Jutel, SPC Co-ordinator Angel Mazon, Web Editor Olympia Tsilochristou, Web Editor Michael Walker, Executive Director II EAACI Executive Committee GLOBAL ATLAS OF ALLERGY contributors Azza Abdel-Gadir, PhD Zürich, Switzerland Montpellier, France Division of Immunology, Boston Mark Ballow, MD Onur Boyman, MD Children’s Hospital. Department Division of Allergy and Immunology, Department of Clinical Immunology, of Pediatrics, Harvard Medical University of South Florida University Hospital Zurich, Zurich, School. Morsani School of Medicine, All Switzerland. Ioana Agache, MD Children’s Hospital, St Petersburg Gert Jan Braunstahl, MD Dept, of Allergy and Clinical USA St. Franciscus Gasthuis Rotterdam, Immunology, Transylvania Nuray Bayar Muluk, MD The Netherlands University of Brasov, Faculty of Dept Otorhinolaryngology,-Kırıkkale Medicine Heimo Breiteneder, PhD University, Turkey Department of Pathophysiology Cezmi A. Akdis, MD Thomas Bieber, MD, PhD, MDRA and Allergy Research, Medical Swiss Institute of Allergy and Asthma Department of Dermatology and University of Vienna, Austria Research (SIAF), University of Allergy, University Medical Center, Zurich, Davos, Switzerland Knut Brockow, MD Friedrich-Wilhelms University of Christine Kühne – Center for Allergy Department of Dermatology Bonn, Germany Research and Education (CK- and AllergologyBiederstein, CARE), Davos, Switzerland M. Beatrice Bilò, MD TechnischeUniversitätMünchen, Germany. Medical Faculty, University of Zurich Allergy Unit - Department of Internal Medicine – University Hospital Mübeccel Akdis, MD, PhD A. Wesley Burks, MD Ospedali Riuniti di Ancona - Italy Department of Pediatrics, University Swiss Institute of Allergy and Asthma Research (SIAF), University of Carsten Bindslev-Jensen, MD of North Carolina at Chapel Hill, Zurich, Davos, Switzerland Odense Research Center for Chapel Hill ,USA Anaphylaxis, Odense Denmark Walter J. Ammann, PhD Robert K. Bush, MD Odense University Hospital, Odense Global Risk Forum (GRF) Davos, University of Wisconsin-Madison, Switzerland Denmark U.S.A Abena S. Amoah, MD Leif Bjemer, MD Jeroen Buters, PhD Department of Parasitology, Leiden Lund University, Department Center for Allergy & Environment University Medical Center, Leiden, of Respiratory Medicine and (ZAUM), Technische Universität The Netherlands Allergology, Sweden München and Helmholtzzentrum Department of Parasitology, Noguchi Barbara Bohle, PhD München, Germany Memorial Institute for Medical Department of Pathophysiology EAACI Interest Group Aerobiology Research, Accra, Ghana and Allergy Research and and Air Pollution Evangelos Andreakos, PhD Christian Doppler Laboratory Moisés A. Calderón, MD Biomedical Research Foundation, for Immunomodulation, Division Section of Allergy and Clinical Academy of Athens, Greece of Cellular Allergology, Medical Immunology, Imperial College University of Vienna, Vienna, London, NHLI, Royal Brompton Isabella Annesi-Maesano, MD Austria French Institute of Health and Hospital, London, UK. Medical Research, Epidemiology Matteo Bonini, MD Victòria Cardona, MD, PhD of Allergic and Respiratory Department of Public Health and Allergy Section, Department of Diseases (EPAR), France Infectious Diseases “Sapienza” Internal Medicine. Hospital University of Rome, Italy Claus Bachert, MD UniversitariValld’Hebron, Upper Airways Research Laboratory, Sergio Bonini, MD Barcelona, Spain University of Ghent, Ghent, Department of Internal Medicine, Kai-Håkon Carlsen, MD Belgium; Second University of Naples, Italy (Paediatric respiratory medicine and Division of ENT Diseases, CLINTEC, Jean Bousquet, MD allergology), University of Oslo, Karolinska Institutet Stockholm, University of Montpellier,France Institute for Clinical Medicine Sweden WHO Global Alliance Against and Oslo University Hospital, Barbara Ballmer-Weber, MD Chronic Respiratory Diseases Department of Paediatrics, Oslo, Department of Dermatology, (GARD) Norway University Hospital Zürich, Director of the WHO Collaborating Jean-Christoph Caubet, MD Switzerland University Hospital Centre for Asthma and Rhinitis in Department of Child and Adolescent, Contributors III GLOBAL ATLAS OF ALLERGY University Hospitals of Geneva Imperial College London, United Philippe Gevaert, MD, PhD and Medical School of the Kingdom. Dept Otorhinolaryngology, Ghent University of Geneva, Geneva, EAACI Patient Organisation University Hospital Switzerland Committee, Stefanie Gilles, PhD Yih-Chih Chan, MD Philippe Eigenmann, MD Institute for environmental medicine, King’s College London, London, University Hospitals of Geneva, UNIKA-T, TechnischeUniversität United Kingdom Geneva, Switzerland Munich, Germany Talal Chatila, MD Veit Erpenbeck, PhD Christine Kühne Center for Allergy Division of Immunology, Boston Novartis Institutes for Biomedical Research and Education (CK- Children’s Hospital/ Department Research, Basel, Switzerland Care), Davos, Switzerland of Pediatrics, Harvard Medical Claude Favrot, Dr .Vet. Hannah Gould, PhD School. Dermatology Service, Clinic for Division of Cell and Molecular R. Sharon Chinthrajah, MD Small Animal Internal Medicine, Biophysics and Division of Allergy, Division of Immunology and Allergy, Vetsuisse Faculty, University of Asthma and Lung Biology, Allergy Department of Pediatrics, Zurich, Zurich, Switzerland and Asthma Group in the Division Stanford University, Stanford, Fatima Ferreira, PhD of Cell and Molecular Biophysics USA Department of Molecular Biology, King’s College London, London, Tomás Chivato Pérez, MD Christian Doppler Laboratory for United Kingdom University CEU San Pablo, Madrid, Allergy Diagnosis and Therapy, Clive E. Grattan, MD Spain Saltzburg, Austria Norfolk and Norwich University Cemal Cingi, MD Michael B. Foggs, MD Hospital, UK Dept Otorhinolaryngology, Eskisehir President American College of Hans Grönlund, PhD Osmangazi University, Turkey Allergy, Asthma & Immunology Karolinska Institutet, Therapeutic Linda Cox, MD Dept of Allergy and Immunology, Immune Design Unit, Department Allergy and Asthma Center, Fort Advocate Health Care, Chicago, of Clinical Neuroscience, Center Lauderdale, Florida, USA United States for Molecular Medicine Reto Crameri, PhD Remo Frei, PhD Karolinska University Hospital Swiss Institute of Allergy and Asthma Swiss Institute of Allergy and Asthma Tari Haahtela, MD Research (SIAF), University of Research (SIAF), University of Skin and Allergy Hospital, Helsinki Zürich, Davos, Switzerland Zurich, Davos, Switzerland University Hospital, Finland Adnan Custovic, MD, PhD Christine Kühne-Center for Allergy Viktor Hafner, PhD University of Manchester, UK Research and Education, Davos Landesgeschäftsstelle Wien, Öster- Janet Davies, PhD Anthony J. Frew, MD reichische Apothekerkammer, Lung and Allergy Research Department of Respiratory Medicine, Austria Centre, School of Medicine, Royal Sussex County Hospital, Susanne Halken, MD, DMSci The University of Queensland, Brighton, UK Hans Christian Andersen Children’s Translational Research Institute, Gabriele Gadermaier, MD Hospital, Odense University Woolloongabba, Queensland, Department of Molecular Biology, Hospital, Denmark Australia Christian Doppler Laboratory for Firdaus Hamid, MD Jan G. R. de Monchy, MD Allergy Diagnosis and Therapy, Department of Parasitology, Leiden University of Groningen, University University of Salzburg, Austria University Medical Center, Leiden, Medical Center Groningen, The Stephen J. Galli, MD The Netherlands Netherlands Stanford Center for Genomics and Department of Microbiology, Pascal Demoly, MD Personalized Medicine Faculty of Medicine, Hasanuddin University Hospital of Montpellier, Professor Stanford University, USA, University, Makassar, Indonesia France Chair, Department of Pathology Catherine M. Hawrylowicz, PhD Günnur Deniz, PhD James Gardner, RN Dip MRC and Asthma UK Centre for Istanbul University, Experimental Department of Child Health, Royal Allergic Mechanisms in Asthma,
Recommended publications
  • Original Articles International Patterns of Tuberculosis and the Prevalence of Symptoms of Asthma, Rhinitis, and Eczema
    Thorax 2000;55:449–453 449 Original articles Thorax: first published as 10.1136/thorax.55.6.449 on 1 June 2000. Downloaded from International patterns of tuberculosis and the prevalence of symptoms of asthma, rhinitis, and eczema Erika von Mutius, Neil Pearce, Richard Beasley, Soo Cheng, Ondine von Ehrenstein, Bengt Björkstén, Stephan Weiland, on behalf of the ISAAC Steering Committee Abstract national patterns of the prevalence of these Background—An ecological analysis was diseases2 are largely unknown. In particular, conducted of the relationship between they cannot be explained by the established tuberculosis notification rates and the putative risk factors such as allergen exposure prevalence of symptoms of asthma, aller- and air pollution which do not appear to be gic rhinoconjunctivitis, and atopic eczema strongly related to the underlying population in 85 centres from 23 countries in which prevalence.2–5 This has led to consideration of standardised data are available. These factors that may programme the initial suscep- essentially comprised countries in Europe tibility to asthma and/or atopy which have as well as the USA, Canada, Australia, and changed in temporal association with the New Zealand. increasing trends in prevalence worldwide, are Methods—Tuberculosis notification rates consistent with international prevalence pat- were obtained from the World Health terns, and for which biological plausibility exists Organization. Data on the prevalence of with respect to an underlying mechanism. symptoms of asthma, rhinitis, and eczema One such hypothesis is that the lack of expo- in 235 477 children aged 13–14 years were sure in early childhood to infections such as University Children’s based on the responses to the written and tuberculosis, measles, and diphtheria may Hospital, Klinikum video questionnaires from the Inter- increase the risk of developing atopic disorders http://thorax.bmj.com/ Innenstadt, Munich, national Study of Asthma and Allergies in 67 Germany such as asthma.
    [Show full text]
  • Gene-Environment Interactions in Chronic Inflammatory Disease
    commentarY Gene-environment interactions in chronic inflammatory disease Harald Renz, Erika von Mutius, Per Brandtzaeg, William O Cookson, Ingo B Autenrieth & Dirk Haller Chronic inflammatory diseases represent a major challenge for both clinical research and patient care, and evidence indicates that these disorders develop as a result of complex gene-environment interactions. Better understanding of their cause-and-effect relationship is the basis for emerging proposals for therapy and prevention. ince the end of World War II there has been The European Science Foundation brought polymorphisms, which has shown that there Sa substantial increase in the incidence of together an international group of experts on are overlapping susceptibility genes in these chronic inflammatory disease that seems to fol- subjects ranging from epidemiology to epigenet- inflammatory disorders3. A prototypic example low a geographical pattern of industrialization ics for a 5-day meeting (19–22 October 2010) in is the discovery of polymorphisms in ORMDL3 and urban living1. This includes allergic condi- Barcelona, Spain2, intended to help define stra- in both asthma and IBD4,5. tions (asthma, allergic rhinoconjunctivitis, food tegic directions for research into this increasing Despite the identification of many potential allergies and eczema), as well as autoimmune public health concern. In this first meeting of the susceptibility genes6,7, their individual effects disorders such as type 1 diabetes, chronic inflam- Forward Look initiative of the European Science seem to be quite modest. Thus, for many dis- matory bowl disease (IBD) and neurodegenera- Foundation, discussions focused on the grand eases, the alleles that have been identified by tive disease. Genetics cannot account for the challenges that face research into gene-envi- genome-wide association studies explain only increase in prevalence over time (Fig.
    [Show full text]
  • Childhood Allergies and Asthma: New Insights
    Available online at www.sciencedirect.com ScienceDirect Childhood allergies and asthma: New insights on environmental exposures and local immunity at the lung barrier 1 1,2 Hermelijn H Smits , Lucie¨ n EPM van der Vlugt , 3,4 2 Erika von Mutius and Pieter S Hiemstra While certain bacteria and respiratory viruses promote local mucus-producing goblet cells and club cells. It not only inflammation and disease onset, a more diverse colonization of acts as a selective physical barrier against inhaled com- the different species in the (gut) microbiome may be linked to ponents, but is also actively involved in host defense, more regulatory responses and protection against asthma and inflammation and immunity [1]. This is illustrated by the allergies. These processes are also influenced in part by food ability of airway epithelial cells to mount robust antimi- intake, both targeting the composition of the gut microbiome crobial responses, produce pro-inflammatory mediators and influencing the immune system via metabolites. Early life and contribute to resolving inflammation. Airway epithe- environmental microbial exposure also contributes to lial cells are also actively involved in regulation of adap- protection against asthma and allergy and is linked with an tive immunity, and may orchestrate Th2 immunity and early activation of the innate immune system and the tolerance in allergy and asthma by for example recruiting development of regulatory immune responses. Although and activating dendritic cells (DC) and type 2 innate greater mechanistic insight is needed, it is tempting to lymphoid cells (ILC2) [2]. Recent studies have highlight- speculate that part of the environmental effect can be ed a role for the epithelial barrier and its interaction with explained by modulation of the microbiome composition at the innate immune system in preventing or reducing mucosal surfaces, epithelial barrier function and/or local allergic and/or asthmatic symptoms [3,4].
    [Show full text]
  • Series Asthma 2020 1 Primary Prevention of Asthma: from Risk and Protective Factors to Targeted Strategies for Prevention Rachel
    20TL11343 THELANCET-D-20-11343R1 Series [PII_REPLACE] Rachel B Embargo: September 7, 2020—23:30 (BST) This version saved: 11:07, 04-Sep-20 Doctopic: Review and Opinion Asthma 2020 1 Primary prevention of asthma: from risk and protective factors to targeted strategies for prevention Erika von Mutius, Hermelijn H Smits Asthma is a complex disease that often starts in childhood. Genomic and environmental factors as well as aberrant Published Online immune maturation early in life can contribute to the onset of disease, with great disparity over time and geographical September 7, 2020 https://doi.org/10.1016/ regions. Epidemiological studies have scrutinised environmental exposures and attempted to translate these PII exposures into prevention strategies. Some approaches for patients with asthma have been successful (eg, smoking See Comment Lancet Respir Med ban, the Finnish Asthma Programme), and primary prevention of wheeze in pre-school children (age 0–5 years) by 2020; published online Sept 7. the supplementation of vitamin D or fish oil, or both, to pregnant women seems promising. Several recent prevention http://dx.doi.org/10.1016/ initiatives are based on strong asthma-protective environmental microbial exposures associated with traditional rural S2213-2600(20)30400-8 lifestyles. Preclinical studies with various bacterial lysates, bacterial and dietary metabolites, or helminthic compounds This is the first in a Series of have yielded promising results that await translation into clinical practice. Given the immense societal and individual three papers about reducing the burden of asthma burden of asthma, there is an urgent need to further develop novel strategies to eradicate the disease.
    [Show full text]
  • The Interrelations Between the Skin Microbiota, Allergic Diseases and Exposure to Microbes in Residential Environments
    The biodiversity hypothesis of allergy: The interrelations between the skin microbiota, allergic diseases and exposure to microbes in residential environments JENNI LEHTIMÄKI LUOVA - Doctoral Programme in Wildlife Biology Research Department of Biosciences, Faculty of Biological and Environmental Sciences University of Helsinki ACADEMIC DISSERTATION To be presented for public examination with the permission of the Faculty of Biological and Environmental Sciences of the University of Helsinki in Lecture hall 2, Infocenter Korona (Viikinkaari 11), on December 1st at 12.00 o’clock noon. HELSINKI 2017 SUPERVISED BY: Professor Ilkka Hanski (2014-2016) University of Helsinki Docent Lasse Ruokolainen University of Helsinki Professor Tiina Laatikainen National Institute for Health and Welfare; University of Eastern Finland MEMBERS OF THE THESIS ADVISORY COMMITTEE: Professor Tari Haahtela Helsinki University Central Hospital Docent Kimmo Saarinen Allergy and Asthma Federation Research Unit REVIEWED BY: Professor Erika von Mutius Munich University Children's Hospital Docent Anne Salonen University of Helsinki EXAMINED BY: Professor Harald Renz Philipps University of Marburg CUSTOS: Assistant Professor Arild Husby University of Helsinki ISBN 978-951-51-3837-8 (paperback) ISBN 978-951-51-3838-5 (PDF) http://ethesis.helsinki.fi Unigrafia Helsinki 2017 To all children, parents, dogs, dog owners, and daycare-workers who made this possible. Contents ABSTRACT 6 TIIVISTELMÄ 7 SUMMARY 9 1. INTRODUCTION ................................................................................................................................
    [Show full text]
  • German Center for Lung Research ANNUAL REPORT
    German Center for Lung Research ANNUAL REPORT 2017 Translational Research to Combat Widespread Lung Diseases Table of Contents Foreword 2 About the DZL: Science – Translation in the Focus of Research 3 Disease Areas 4 Asthma and Allergy 4 Chronic Obstructive Pulmonary Disease (COPD) 6 Cystic Fibrosis (Mucoviscidosis) 8 Pneumonia and Acute Lung Injury 10 Diffuse Parenchymal Lung Disease (DPLD) 12 Pulmonary Hypertension 14 End-Stage Lung Disease 16 Lung Cancer 18 Platforms and Infrastructure 20 Biobanking & Data Management Platform 20 Imaging Platform 22 DZL Technology Transfer Consortium 25 Clinical Trial Board and Clinical Studies in the DZL 26 DZL Collaborations, Partnerships, and Networks 28 Promotion of Junior Scientists and Equal Opportunities 34 The Public Face of the DZL 36 Highlights of the Year 2017 40 The German Centers for Health Research 43 DZL Organization 44 Selected Prizes and Awards 46 DZL Member Institutions and Sites 47 Finance and Personnel 53 1 Foreword Prof. Dr. Werner Seeger Prof. Dr. Hans-Ulrich Prof. Dr. Klaus F. Rabe Prof. Dr. Erika v. Mutius Prof. Dr. Tobias Welte Chairman of the Board Kauczor Board Member Board Member Board Member Board Member The anniversary year 2016 let us gain insights into the great research efforts of the scientists at the partner institutions through- out Germany, whose achievements are already put into practice in numerous occasions for the prevention, diagnosis, and treat- ment of lung diseases. 2017 lets us now look further ahead, taking a closer look at the promising future of the German Center for Lung Research (DZL). In summer 2017, the German Centers for Health Research (DZG) received a great accolade from the German Council of Scienc e and Humanities (Wissenschaftsrat) with its “Recommendations for the Further Development of the DZG”.
    [Show full text]
  • Forschungsbericht 2015/2016 2 Inhaltsverzeichnis
    FORSCHUNGSBERICHT 2015/2016 2 Inhaltsverzeichnis Vorwort ���������������������������������������������������������������������������������������������5 Priority Research Area Infections Leibniz Lungenzentrum - nomen est omen - �����������������������������������6 Bioanalytical Chemistry ������������������������������������������������������������������74 EvoLUNG �����������������������������������������������������������������������������������������10 Biophysics ����������������������������������������������������������������������������������������78 Postdocs - zwischen Baum und Borke? �������������������������������������������12 Cellular Microbiology ����������������������������������������������������������������������82 Clinical Infectious Diseases �������������������������������������������������������������86 Menschen / People Coinfection ��������������������������������������������������������������������������������������90 Sven Perner �������������������������������������������������������������������������������������16 Diagnostic Mycobacteriology (NRC) �����������������������������������������������94 Xinhua Yu & Gabriela Riemekasten ������������������������������������������������17 Immunobiophysics ��������������������������������������������������������������������������98 Katharina Kranzer ����������������������������������������������������������������������������18 Infection Immunology �������������������������������������������������������������������102 Katarzyna Duda �������������������������������������������������������������������������������19
    [Show full text]
  • When Allergies Go West
    OUTLOOK ALLERGIES erms can be good for us. This ‘hygiene hypothesis’ claims the urban ‘West- ern’ lifestyle, with its relatively limited Gexposure to infectious agents during child- hood, might be behind the post-war epi- JOE POLILLIO/GETTY demics of asthma, eczema and food allergies. But can the explosion in allergies in the devel- oped world really be explained so simply? A more complicated theory is emerging. For, while it is apparent that there is some- thing about Western living that increases the risk of developing allergies, research has shown that it’s not just a culture of antibacterial soaps, antibiotics and excessive cleanliness that’s to blame. There is evidence to suggest there is more about the way children are raised — where they are raised, what they are fed and how many siblings they have — that influences their burgeoning immune systems. It’s not just that their exposure to microbes or potential allergens seems to be limited. Sanitary liv- ing conditions disrupt the delicate balance between our bodies and a complex ecology of microbes and parasites with which we co- evolved, and through which our immune systems are balanced and regulated (see ‘Gut reaction’, page S5). In 1989, epidemiologist David Strachan proposed the theory that a reduced exposure to dirt could render a person prone to allergy. The idea originally had a far narrower scope and, as Strachan, then at the London School of Hygiene and Tropical Medicine, but now at St George’s University of London, is at pains to point out, he didn’t actually use the term ‘hygiene hypothesis’.
    [Show full text]
  • Indoor Bacterial Microbiota and the Development of Asthma by 10.5 Years of Age
    Journal Pre-proof Indoor Bacterial Microbiota and the Development of Asthma by 10.5 years of age Anne M. Karvonen, PhD, Pirkka V. Kirjavainen, PhD, Martin Täubel, PhD, Balamuralikrishna Jayaprakash, MSc, Rachel I. Adams, PhD, Joanne E. Sordillo, ScD, Diane R. Gold, MD, MPH, Anne Hyvärinen, PhD, Sami Remes, MD, MPH, Erika von Mutius, MD, Juha Pekkanen, MD PII: S0091-6749(19)31033-4 DOI: https://doi.org/10.1016/j.jaci.2019.07.035 Reference: YMAI 14123 To appear in: Journal of Allergy and Clinical Immunology Received Date: 7 September 2017 Revised Date: 6 June 2019 Accepted Date: 11 July 2019 Please cite this article as: Karvonen AM, Kirjavainen PV, Täubel M, Jayaprakash B, Adams RI, Sordillo JE, Gold DR, Hyvärinen A, Remes S, von Mutius E, Pekkanen J, Indoor Bacterial Microbiota and the Development of Asthma by 10.5 years of age, Journal of Allergy and Clinical Immunology (2019), doi: https://doi.org/10.1016/j.jaci.2019.07.035. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2019 Published by Elsevier Inc.
    [Show full text]
  • Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk
    This PDF is available from The National Academies Press at http://www.nap.edu/catalog.php?record_id=18998 Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk ISBN Committee on Strategies for Responsible Sharing of Clinical Trial Data; 978-0-309-31629-3 Board on Health Sciences Policy; Institute of Medicine 280 pages 6 x 9 PAPERBACK (2015) Visit the National Academies Press online and register for... Instant access to free PDF downloads of titles from the NATIONAL ACADEMY OF SCIENCES NATIONAL ACADEMY OF ENGINEERING INSTITUTE OF MEDICINE NATIONAL RESEARCH COUNCIL 10% off print titles Custom notification of new releases in your field of interest Special offers and discounts Distribution, posting, or copying of this PDF is strictly prohibited without written permission of the National Academies Press. Unless otherwise indicated, all materials in this PDF are copyrighted by the National Academy of Sciences. Request reprint permission for this book Copyright © National Academy of Sciences. All rights reserved. Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk Sharing Clinical Trial Data Maximizing Benefits, Minimizing Risk Committee on Strategies for Responsible Sharing of Clinical Trial Data Board on Health Sciences Policy PREPUBLICATION COPY: UNCORRECTED PROOFS Copyright © National Academy of Sciences. All rights reserved. Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk THE NATIONAL ACADEMIES PRESS 500 Fifth Street, NW Washington, DC 20001 NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.
    [Show full text]
  • THELANCET-D-16-01609R2 Title: After Asthma
    Elsevier Editorial System(tm) for The Lancet Manuscript Draft Manuscript Number: THELANCET-D-16-01609R2 Title: After asthma - redefining airways diseases. A Lancet commission Article Type: Other Corresponding Author: Professor Ian Pavord, DM FRCP Corresponding Author's Institution: University of Oxford First Author: Ian D Pavord, FMedSci Order of Authors: Ian D Pavord, FMedSci; Richard Beasley, MD; Alvar Agusti, MD; Gary P Anderson, PhD; Elisabeth Bel, MD; Guy Brusselle, MD; Paul Cullinan, MD; Adnan Custovic, MD; Francine M Ducharme, MD; John V Fahy, MD; Urs Frey, MD; Peter Gibson, MD; Liam G Heaney, MD; Pat Holt, MD; Marc Humbert, MD; Clare Lloyd, PhD; Guy Marks, MD; Fernando D Martinez, MD; Peter D Sly, MD; Erika von Mutius, MD; Sally Wenzel, MD; Heather Zar, MD; Andrew Bush, MD Abstract: No abstract for this article type *Manuscript After asthma – redefining airways diseases. A Lancet commission Ian D Pavord1, Richard Beasley2, Alvar Agusti3, Gary P Anderson4, Elisabeth Bel5, Guy Brusselle6, Paul Cullinan7, Adnan Custovic8, Francine M Ducharme9, John V Fahy10, Urs Frey11, Peter Gibson12, Liam G Heaney13, Patrick G Holt14, Marc Humbert15, Clare Lloyd16, Guy Marks17, Fernando D Martinez18, Peter D Sly19, Erika von Mutius20, Sally Wenzel21, Heather J Zar22, Andy Bush8,23 1Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, UK; 2Medical Research Institute of New Zealand, Wellington, New Zealand ; 3Respiratory Institute, Hospital Clinic, IDIBAPS, Univ. Barcelona and CIBER Enfermedades Respiratorias (CIBERES),
    [Show full text]
  • Prevalence Ofasthma and Allergic Disorders Among Children in United
    Prevalence ofasthma and allergic disorders among children in united Germany: a descriptive comparison BMJ: first published as 10.1136/bmj.305.6866.1395 on 5 December 1992. Downloaded from Erika von Mutius, Christian Fritzsch, Stephan K Weiland, Gabriele Roll, Helgo Magnussen Abstract The reunification of Germany provided a unique Objectives-To compare the prevalence of opportunity to study two genetically similar popula- asthma and allergic disorders among children in tions who over the past 45 years have been exposed to Munich, western Germany, and Leipzig, eastern different living conditions and levels of environmental Germany, where environmental exposure, particu- pollution. In particular, the type of air pollution differs larly air concentrations of sulphur dioxide and greatly between westem and eastern Germany. The particulate matter, and living conditions have objective of this study was to compare the prevalences differed over the past 45 years. of asthma and allergic disorders among children in Design-Prevalence surveys among school- Munich, western Germany, and Leipzig, eastern children aged 9-11 years in Leipzig and Munich. Self Germany, where air concentrations of sulphur dioxide completion of written questionnaire by the child- are particularly high. A prevalence survey of 9-1 1 year ren's parents and lung function measurements. old children was carried out in both cities by the same Subjects-1051 children in Leipzig and 5030 in methods. Munich. Setting-Primary schools. Main outcome measures-Reported lifetime Subjects and methods prevalence of asthma and allergic disorders, and STUDY AREAS AND POPULATIONS bronchial hyperresponsiveness assessed by cold air Munich is a city with moderate industry and heavy inhalation challenge.
    [Show full text]